Clinical trials: Syndrome
Dry Eye Syndromes
Dose-response Study of OPC-12759 Ophthalmic Suspension
The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.
- Trial name
- NCT00234078
- Testing
- 0.5% OPC-12759, 1% OPC-12759, 2% OPC-12759
- Where
- Japan
- Volunteers
- 290 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Paroxysmal Nocturnal Hemoglobinuria, PNH
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.
- Trial name
- NCT02605993
- Testing
- Ravulizumab
- Where
- 16 sites in Canada, France and 5 more
- Volunteers
- 26 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Diarrhea-predominant Irritable Bowel Syndrome
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.
- Trial name
- NCT01358708
- Testing
- LACTEOL® 340 mg
- Where
- 8 sites in France, Germany
- Volunteers
- 26 people
- Sponsor
- Forest Laboratories
Hodgkin's Disease, Non Hodgkin's Lymphoma
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
The central hypothesis of this study is that use of a less toxic chemotherapy preparative regimen for allogeneic hematopoietic stem cell transplantation in combination with T cell depletion with alemtuzumab for patients with high…
- Conditions
- Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia
- Trial name
- NCT00597714
- Testing
- Non-myeloablative Stem Cell Transplantation
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- David Rizzieri, MD
HIV Infections
China Antiretroviral Treatment Adherence for Life
This study focuses on collecting and analyzing quantitative data related to adherence to antiretroviral treatment from patients in Dali, China, over a one-year time-frame and generating preliminary data on an intervention…
- Trial name
- AFL (NCT00661258)
- Testing
- Electronic drug monitoring feedback data
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Boston University
Acute Coronary Syndrome, Thrombosis
Hormones Inflammation and Thrombosis
The investigators are attempting to determine if the response to aspirin in women is related to the level of estrogen and progesterone that a woman has.
- Trial name
- HIT2 (NCT01875185)
- Testing
- Aspirin 81 mg
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Paroxysmal Nocturnal Hemoglobinuria
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
The primary objective of the study is: To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of treatment, in patients with PNH who switch…
- Trial name
- ACCESS 2 (NCT05131204)
- Testing
- Cemdisiran, Eculizumab, Pozelimab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
- Trial name
- NCT00306384
- Testing
- Alogliptin
- Where
- 114 sites in United States, Argentina and 10 more
- Volunteers
- 3,323 people
- Sponsor
- Takeda
Short Bowel Syndrome
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
The main aims of the study are to check for side effects from teduglutide. Participants will receive a daily injection of teduglutide just under the skin (subcutaneous) for 24 weeks. Then they are followed up for another 4 weeks.
- Trial name
- NCT05027308
- Testing
- Teduglutide
- Where
- 6 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Takeda
Fragile X Syndrome
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
This trial will evaluate the efficacy and safety of ZYN002, a clear cannabidiol gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X Syndrome…
- Trial name
- CONNECT-FX (NCT03614663)
- Testing
- ZYN002 - Cannabidiol Transdermal Gel
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 212 people
- Sponsor
- Zynerba Pharmaceuticals, Inc.
HIV Infections
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy…
- Trial name
- NCT01302847
- Testing
- DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
- Where
- 33 sites in United States, Botswana and 6 more
- Volunteers
- 181 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Eosinophilic Granulomatous Vasculitis
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC)…
- Trial name
- MANDARA (NCT04157348)
- Testing
- Benralizumab, Mepolizumab
- Where
- 50 sites in United States, Belgium and 7 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
HIV/AIDS
Impact of Metformin on Immuno-virologic Parameters in HIV
Non-diabetic, aviremic HIV-infected individuals on antiretroviral therapy (ART) will be randomized to metformin therapy or to observation for 72 weeks.
- Trial name
- NCT04500678
- Testing
- Metformin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Hawaii
HIV/AIDS, Housing Problems
Enhanced Housing Placement Assistance
Randomized controlled trial of housing placement assistance for homeless persons with HIV
- Trial name
- EHPA (NCT03334825)
- Testing
- Enhanced housing placement assistance, Standard housing placement assistance
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- New York City Department of Health and Mental Hygiene
Leukemia, Lymphoma
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2 cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of allopurinol.
- Trial name
- NCT01200485
- Testing
- Rasburicase, Allopurinol
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Restless Leg Syndrome
Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
The purpose of this research study is to compare the safety and effectiveness of local injections of botulinum toxin A (Xeomin®) to an inactive test substance (placebo) in a medical condition called Restless Leg Syndrome.
- Trial name
- NCT01931878
- Testing
- incobotulinumtoxinA
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Myelodysplastic Syndrome
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
This is a phase II study of lenalidomide in patients with myelodysplastic syndrome (MDS) and with acute myeloid leukemia (AML) with trilineage dysplasia. Patients will receive two cycles of lenalidomide.
- Trial name
- NCT00867308
- Testing
- Lenalidomide 50 mg, Lenalidomide 15 mg
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HIV Disease
Autonomic Neuropathy, GI Motility, and Inflammation in HIV
The purpose of this study is to explore a possible link between the autonomic nervous system and immune function in patients with HIV.
- Trial name
- ANGI (NCT02850276)
- Testing
- Pyridostigmine
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.